IPCA Laboratories Limited (IN:IPCALAB)

:IPCALAB

IPCALAB

IPCA Laboratories Limited

RESEARCH TOOLSreports

Want to see IN:IPCALAB full AI Analyst Report?

IPCA Laboratories Limited (IPCALAB) Price & Analysis

2 Followers

IPCALAB Stock Chart & Stats

₹1403.75

-₹42.20(-2.43%)

At close: Jan 08 4:00 PM EST

₹1403.75

-₹42.20(-2.43%)

Day’s Range― - ―

52-Week Range₹1,252.95 - ₹1,679.45

Previous CloseN/A

Volume578.66K

Average Volume (3M)6.78K

Market Cap

₹382.39B

Enterprise Value₹389.19B

Total Cash (Recent Filing)₹12.83B

Total Debt (Recent Filing)₹12.79B

Price to Earnings (P/E)34.6

Beta0.18

Next Earnings

Aug 06, 2026

EPS Estimate

10.6

Next Dividend Ex-DateN/A

Dividend Yield0.28%

Share Statistics

EPS (TTM)32.78

Shares Outstanding253,659,230

10 Day Avg. Volume6,645

30 Day Avg. Volume6,776

Financial Highlights & Ratios

PEG Ratio0.65

Price to Book (P/B)5.04

Price to Sales (P/S)4.21

P/FCF Ratio83.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)58.28

Revenue Forecast (FY)₹107.68B

Bulls Say, Bears Say

Bulls Say

Low LeverageA conservative balance sheet with debt-to-equity near 0.10 provides structural resilience: lower interest burden, greater capacity to fund capex or regulatory compliance, and optionality for acquisitions or downturns. This durable financial flexibility supports long-term stability.

Diversified Pharma ModelOperating both finished formulations and APIs across domestic and export markets creates multiple, persistent revenue streams. The mix of branded, generic and B2B supply reduces single-market dependence, supporting steadier earnings and mitigating product- or geography-specific shocks over months.

Sustained ProfitabilityMaintaining mid-40s gross margins and near-double-digit net margins indicates structurally profitable operations and manufacturing scale. Even with compression, these margins support reinvestment and cash generation, underpinning long-term competitive capability in specialty and generic drugs.

Bears Say

Margin CompressionSustained margin erosion suggests worsening mix, cost pressure, or pricing weakness that can structurally reduce returns on capital. If persistent, compressed margins limit reinvestment, dividend capacity and ability to absorb regulatory or R&D spend, weighing on long-term profitability.

Slowing Revenue GrowthTop-line growth slowing to low single digits indicates reduced organic momentum or market saturation in key segments. Over a multi-month horizon, slower revenue expansion constrains earnings leverage, makes margin recovery harder, and increases reliance on efficiency or M&A to sustain earnings growth.

Moderate FCF ConversionSub‑par free cash flow conversion implies working capital needs or capex absorb a sizeable share of earnings. Lower cash conversion reduces capacity for shareholder returns, debt reduction or strategic investments, and increases sensitivity to cyclical cash pressures over the medium term.

IPCA Laboratories Limited News

Ipca Laboratories Closes Insider Trading Window Ahead of FY26 Results

IPCA Laboratories Limited ( ($IN:IPCALAB) ) just unveiled an announcement. Ipca Laboratories has announced that its trading window...

3M ago

Ipca Laboratories to Sell US Step-Down Subsidiary, Updates Registered Office Details for Project Filings

IPCA Laboratories Limited ( ($IN:IPCALAB) ) just unveiled an announcement. Ipca Laboratories’ board has approved the sale of...

5M ago

IPCA Laboratories Expands with New German Subsidiary

IPCA Laboratories Limited ( ($IN:IPCALAB) ) has shared an update. IPCA Laboratories Limited has announced the incorporation of...

8M ago

IPCA Laboratories Announces Trading Window Closure

IPCA Laboratories Limited ( ($IN:IPCALAB) ) has issued an announcement. IPCA Laboratories Limited has announced the closure of...

9M ago

IPCALAB FAQ

What was IPCA Laboratories Limited’s price range in the past 12 months?

IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1679.45 in the past 12 months.

What is IPCA Laboratories Limited’s market cap?

IPCA Laboratories Limited’s market cap is ₹382.39B.

When is IPCA Laboratories Limited’s upcoming earnings report date?

IPCA Laboratories Limited’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.

How were IPCA Laboratories Limited’s earnings last quarter?

IPCA Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹11.8 earnings per share for the quarter, beating the consensus estimate of ₹10.074 by ₹1.726.

Is IPCA Laboratories Limited overvalued?

According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does IPCA Laboratories Limited pay dividends?

IPCA Laboratories Limited pays a Semiannually dividend of ₹2 which represents an annual dividend yield of 0.28%. See more information on IPCA Laboratories Limited dividends here

What is IPCA Laboratories Limited’s EPS estimate?

IPCA Laboratories Limited’s EPS estimate is 10.6.

How many shares outstanding does IPCA Laboratories Limited have?

IPCA Laboratories Limited has 253,659,230 shares outstanding.

What happened to IPCA Laboratories Limited’s price movement after its last earnings report?

IPCA Laboratories Limited reported an EPS of ₹11.8 in its last earnings report, beating expectations of ₹10.074. Following the earnings report the stock price went down -3.753%.

Which hedge fund is a major shareholder of IPCA Laboratories Limited?

Currently, no hedge funds are holding shares in IN:IPCALAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

IPCA Laboratories Limited

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.